<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363684</url>
  </required_header>
  <id_info>
    <org_study_id>19-004543</org_study_id>
    <secondary_id>U19AG063911</secondary_id>
    <nct_id>NCT04363684</nct_id>
  </id_info>
  <brief_title>ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)</brief_title>
  <official_title>ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the
      formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01
      AG045390; funded through 2019) as a single North American research consortium to study FTLD
      for 2019 and beyond.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate
      sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and
      asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and
      informing clinical trial design. The study has two arms: a &quot;longitudinal arm&quot; involving a
      comprehensive assessment of clinical, functional, imaging, and biofluid data collection
      annually, and a &quot;biofluid-focused arm&quot; involving limited clinical data to accompany
      biospecimen collection. For more information: https://www.allftd.org/
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brain Volumes</measure>
    <time_frame>Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</time_frame>
    <description>Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in NIH Examiner Executive Composite Score</measure>
    <time_frame>Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</time_frame>
    <description>Evaluate change in NIH Examiner Executive Composite Score in asymptomatic f-FTLD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Multidomain Impairment Rating (MIR) Scale</measure>
    <time_frame>Baseline, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</time_frame>
    <description>Annual change in MIR score (total score 0-3), which is a new global scale for FTLD that incorporates behavioral, cognitive, and motor dysfunction in the rating.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Neurofilament Light Chain Analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Annual blood samples will be collected to detect changes in plasma neurofilament light chain concentrations</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Frontotemporal Lobar Degeneration (FTLD)</condition>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <condition>Corticobasal Degeneration (CBD)</condition>
  <condition>Behavioral Variant Frontotemporal Dementia (bvFTD)</condition>
  <condition>Semantic Variant Primary Progressive Aphasia (svPPA)</condition>
  <condition>Nonfluent Variant Primary Progressive Aphasia (nfvPPA)</condition>
  <condition>FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Oligosymptomatic PSP (oPSP)</condition>
  <arm_group>
    <arm_group_label>Longitudinal Arm</arm_group_label>
    <description>Annual clinic visits throughout the length of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofluid-Focused Arm</arm_group_label>
    <description>Single clinic visit.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, RNA, plasma, serum, PBMC, CSF (CSF is optional)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will have a referring diagnosis of an FTLD clinical syndrome or will be a
        member of a family with a strong family history of an FTLD syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Longitudinal Arm Inclusion Criteria

        Familial FTLD (f-FTLD) participants (either is acceptable):

          -  members of families in whom at least one member has a known disease-associated
             mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other
             rare genes)

          -  an autosomal dominant family history of a FTLD syndrome (without a known gene)
             verified by medical record review or well-documented family history including family
             members with a medical history consistent with FTLD or a related disorder.

        Sporadic FTLD (s-FTLD) participants:

        Sporadic participants should be symptomatic with no known family history nor a genetic
        mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a
        referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will
        be excluded from longitudinal visits, but their baseline visit will be included in
        comparative datasets. For inclusion in the longitudinal follow-up, participants should meet
        research criteria for one of the following FTLD syndromes:

          -  Progressive Supranuclear Palsy (PSP)

          -  Semantic variant Primary Progressive Aphasia (svPPA)

          -  Nonfluent variant Primary Progressive Aphasia (nfvPPA)

          -  Corticobasal Degeneration (CBD)/Corticobasal Syndrome (CBS)

          -  Behavioral variant Frontotemporal dementia (bvFTD)

          -  Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD/ALS)

        Biofluid-Focused Arm Inclusion Criteria

        Participants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general
        inclusion criteria apply. Participants should meet research criteria (as specified above)
        for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm
        participants do not undergo the same detailed clinical and functional assessments required
        for the longitudinal arm, participants may be included regardless of primary language, as
        long as an appropriately translated consent is available.

        Exclusion Criteria:

          -  Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could
             reasonably explain symptoms in a symptomatic participant.

          -  Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or
             biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.

          -  A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5
             years of onset of dementia), frequent alcohol or other substance intoxication, or
             other neurological disorder.

          -  Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 &lt;
             95% of local laboratory's normal value), unregulated hypothyroidism (TSH &gt;150% of
             normal), HIV positive, renal failure (creatinine &gt; 2), liver failure (ALT or AST &gt; two
             times normal), respiratory failure that requires supplemental oxygen, large confluent
             white matter lesions, significant systemic medical illnesses such as deteriorating
             cardiovascular disease.

          -  Current medication likely to affect CNS functions in the opinion of the site PI.

          -  In the site investigator's opinion, the participant cannot complete sufficient key
             study procedures. The participant may be enrolled into the biofluid-focused arm if
             they can tolerate a blood draw and short clinical exam, but must be able to complete
             at least 75% of study procedures for enrollment into the longitudinal arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Boeve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Boxer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howie Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah K Forsberg, PhD</last_name>
    <phone>507-293-9577</phone>
    <email>forsberg.leah@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilary Heuer, PhD</last_name>
    <phone>415-476-6743</phone>
    <email>hilary.heuer@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Brown</last_name>
      <email>samanthabrown@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Roberson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Chavez</last_name>
      <email>diana.chavez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Mario Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aishwarya Niraula</last_name>
      <email>a2niraula@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Litvan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doug Galasko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Leger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>91358</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Bajorek</last_name>
      <email>lynn.bajorek@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elise Ong</last_name>
      <email>elise.ong@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Boxer, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Worthen</last_name>
      <email>worthen.ann@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Neil Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Pollner</last_name>
      <email>emma.pollner@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Sandra Weintraub, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Fishman</last_name>
      <email>ann.fishman@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Chiadi Onyike, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Krahn</last_name>
      <email>ekrahn@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Nelson</last_name>
      <phone>507-284-9295</phone>
      <email>nelson.kevin1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Boeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washinton University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Nolte</last_name>
      <email>nolte.tina@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nupur Ghoshal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aaron Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Unversity</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masood Manoochehri</last_name>
      <email>mm2626@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Huey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Nicely</last_name>
      <email>karen_nicely@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Ferrall</last_name>
      <email>jferrall@neurology.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Kaufer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fran Lissemore</last_name>
      <phone>216-464-6203</phone>
      <email>frances.lissemore@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Brain Appleby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Bove</last_name>
      <email>jessica.bove@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Murray Grossman, MD, EdD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Irwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantz National Alzheimer Center Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Arbones</last_name>
      <email>varbones@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Belen Pascual, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Masdeu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHristina Caso</last_name>
      <email>cdcaso@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kimiko Domoto-Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Banga</last_name>
      <phone>604-822-5009</phone>
      <email>yasmin.banga@vch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Freid</last_name>
      <phone>604-827-1050</phone>
      <email>rachel.freid@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ging-Yuek Robin Hsiung, MD, MHSc, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Mackenzie, MD, MSc, LMCC, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Salvo</last_name>
      <phone>416-507-6880</phone>
      <email>cristina.salvo@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Behnaz Ghazanfari</last_name>
      <email>mailto:behnaz.ghazanfari@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Carmela Tartaglia, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.allftd.org/</url>
    <description>ALLFTD Study Website</description>
  </link>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bradley Boeve</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified subject level data will be shared upon approved data request.</ipd_description>
    <ipd_time_frame>De-identified data will be available for at least the duration of the study.</ipd_time_frame>
    <ipd_access_criteria>Interested researchers must complete a data request through the ALLFTD website. All data requests will be reviewed by a committee for evaluation of scientific merit and feasibility. Please consult the website for additional information regarding this process (https://www.allftd.org/policies).
Approved requests will be delivered in a de-identified manner.</ipd_access_criteria>
    <ipd_url>https://www.allftd.org/data</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

